The combination of Merck's Welireg and Eisai's Lenvima has not yet shown statistical significance in extending overall ...

Results from the global PREVAIL Phase 3 trial showed that gefurulimab met its primary endpoint, demonstrating a statistically significant and ...

At week 52 in a randomized, controlled trial, results suggest that tocilizumab is more effective than methotrexate in ...

Merck & Co (MSD) and Eisai are set to discontinue their Phase III clinical trial for unresectable, non‑metastatic ...

PHOENIX -- A first-in-class oral miR-124 enhancer significantly improved clinical remission and endoscopic outcomes for ...

Rare disease drug development presents unique challenges: patient populations are often minimal, clinical endpoints may not ...

Staloral® Birch Phase III Study successfully meets primary endpoint, demonstrating efficacy in children and adolescents.

As the most immediate and active touchpoint for sensitive data, the endpoint plays a pivotal role in the data security ...

Motex released urgent patches for a critical vulnerability in Lanscope Endpoint Manager that has been exploited in the wild as a zero-day.

The U.S. Cybersecurity and Infrastructure Security Agency (CISA) on Wednesday added a critical security flaw impacting Motex ...